Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor.
Sona M VoraStephen BoydNicholas DennyElizabeth JacksonNoemi B A RoyJo HowardSanne LugthartPublished in: British journal of haematology (2022)
Keyphrases